Il Farmaco

Ligands for expression cloning and isolation of GABA_B receptors
pp. 173-183(11)
Authors: Froestl W.; Bettler B.; Bittiger H.; Heid J.; Kaupmann K.; Mickel S.J.; Strub D.

In silico screening with benzofurane- and benzopyrane-type MDR-modulators
pp. 185-191(7)
Authors: Rebitzer S.; Annibali D.; Kopp S.; Eder M.; Langer T.; Chiba P.; Ecker G.F.; Noe C.R.

Purine and deazapurine nucleosides: synthetic approaches, molecular modelling and biological activity
pp. 193-204(12)
Authors: Cristalli G.; Costanzi S.; Lambertucci C.; Taffi S.; Vittori S.; Volpini R.

Ceramide analogues in apoptosis: a new strategy for anticancer drug development
pp. 205-211(7)
Authors: Macchia M.; Bertini S.; Fogli S.; Giovannetti E.; Minutolo F.; Rapposelli S.; Danesi R.

The discovery of a new potential anticancer drug: a case history
pp. 213-220(8)
Author: Cozzi P.

Anticancer bisquaternary heterocyclic compounds: a ras-ional design
pp. 221-229(9)
Authors: Campos J.; Nunez C.; Daz J.J.; Sanchez R.M.; Gallo M.A.; Espinosa A.

Synthesis and biological evaluation of enantiomerically pure pyrrolyl-oxazolidinones as a new class of potent and selective monoamine oxidase type A inhibitors
pp. 231-241(11)
Authors: Mai A.; Artico M.; Esposito M.; Ragno R.; Sbardella G.; Massa S.

Structural modifications of antisense oligonucleotides
pp. 243-258(16)
Authors: Urban E.; Noe C.R.

Anti-HIV agents: design and discovery of new potent RT inhibitors
pp. 259-263(5)
Authors: Barreca M.L.; Chimirri A.; De Clercq E.; De Luca L.; Monforte A.-M.; Monforte P.; Rao A.; Zappala M.

Cytisine derivatives as ligands for neuronal nicotine receptors and with various pharmacological activities
pp. 265-277(13)
Authors: Boido C.C.; Tasso B.; Boido V.; Sparatore F.

H₃ receptor ligands: new imidazole H₃-antagonists endowed with NO-donor properties
pp. 279-283(5)
Author: Bertinaria M.